ArticleNature genetics2010
Fanconi anemia and breast cancer susceptibility meet again.
Article in Nature genetics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 61 citations in OpenAlex.
- Genome-Wide CRISPR Screens Identify Genome Stability as Regulator of the Cellular Sensitivity to Environmentally Relevant Bisphenol A Exposure.Biomolecules · 2026Article
- Gender-Specific Genetic Predisposition to Breast Cancer:Cancers · 2024Review
- Systematic analysis of Mendelian disease-associated gene variants reveals new classes of cancer-predisposing genes.Genome medicine · 2023Article
- Inherited heterozygous Fanconi anemia gene mutations in a therapy-related CMML patient with a rareFrontiers in oncology · 2022Article
- Article
- The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Review
- Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility.Scientific reports · 2017Article
- Human RAD52 - a novel player in DNA repair in cancer and immunodeficiency.Haematologica · 2017Article
- Novel insights into RAD51 activity and regulation during homologous recombination and DNA replication.Biochemistry and cell biology = Biochimie et biologie cellulaire · 2016Review
- Fanconi anemia pathway defects in inherited and sporadic cancers.Translational pediatrics · 2014Review
- Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells.Journal of cancer prevention · 2014Article
- Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer.Cancer biology & therapy · 2014Review
- TNF-α signaling in Fanconi anemia.Blood cells, molecules & diseases · 2014Review
- Article
- The HsRAD51B-HsRAD51C stabilizes the HsRAD51 nucleoprotein filament.DNA repair · 2013Article
- A novel interplay between the Fanconi anemia core complex and ATR-ATRIP kinase during DNA cross-link repair.Nucleic acids research · 2013Article
- Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia.American journal of human genetics · 2013Article
- FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer.Cell cycle (Georgetown, Tex.) · 2012Article
- Germline RAD51C mutations confer susceptibility to ovarian cancer.Nature genetics · 2012Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new study reports biallelic mutations in RAD51C in a Fanconi anemia-like disorder, while a second study reports monoallelic mutations in the same gene associated with increased breast cancer risk. These findings strengthen the link between Fanconi anemia and breast cancer-associated pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.